A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1
- PMID: 16790789
- PMCID: PMC1489699
- DOI: 10.1128/IAI.00150-06
A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1
Abstract
Antibody (Ab) responses to Bacillus anthracis toxins are protective, but relatively few protective monoclonal antibodies (MAbs) have been reported. Protective antigen (PA) is essential for the action of B. anthracis lethal toxin (LeTx) and edema toxin. In this study, we generated two MAbs to PA, MAbs 7.5G and 10F4. These MAbs did not compete for binding to PA, consistent with specificities for different epitopes. The MAbs were tested for their ability to protect a monolayer of cultured macrophages against toxin-mediated cytotoxicity. MAb 7.5G, the most-neutralizing MAb, bound to domain 1 of PA and reduced LeTx toxicity in BALB/c mice. Remarkably, MAb 7.5G provided protection without blocking the binding of PA or lethal factor or the formation of the PA heptamer complex. However, MAb 7.5G slowed the proteolytic digestion of PA by furin in vitro, suggesting a potential mechanism for Ab-mediated protection. These observations indicate that some Abs to domain 1 can contribute to host protection.
Figures




Similar articles
-
Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen.FEMS Immunol Med Microbiol. 2006 Aug;47(3):436-43. doi: 10.1111/j.1574-695X.2006.00114.x. FEMS Immunol Med Microbiol. 2006. PMID: 16872381 Free PMC article.
-
Monoclonal antibodies directed against protective antigen of Bacillus anthracis enhance lethal toxin activity in vivo.FEMS Immunol Med Microbiol. 2011 Jun;62(1):11-22. doi: 10.1111/j.1574-695X.2011.00782.x. Epub 2011 Feb 2. FEMS Immunol Med Microbiol. 2011. PMID: 21231965
-
Identification of linear epitopes in Bacillus anthracis protective antigen bound by neutralizing antibodies.J Biol Chem. 2009 Sep 11;284(37):25077-86. doi: 10.1074/jbc.M109.022061. Epub 2009 Jul 18. J Biol Chem. 2009. PMID: 19617628 Free PMC article.
-
In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity.Infect Immun. 2007 Nov;75(11):5443-52. doi: 10.1128/IAI.00529-07. Epub 2007 Aug 20. Infect Immun. 2007. PMID: 17709410 Free PMC article.
-
Monoclonal antibody therapies against anthrax.Toxins (Basel). 2011 Aug;3(8):1004-19. doi: 10.3390/toxins3081004. Epub 2011 Aug 15. Toxins (Basel). 2011. PMID: 22069754 Free PMC article. Review.
Cited by
-
CD1d-dependent B-cell help by NK-like T cells leads to enhanced and sustained production of Bacillus anthracis lethal toxin-neutralizing antibodies.Infect Immun. 2010 Apr;78(4):1610-7. doi: 10.1128/IAI.00002-10. Epub 2010 Feb 1. Infect Immun. 2010. PMID: 20123711 Free PMC article.
-
Identification of peptide sequences as a measure of Anthrax vaccine stability during storage.Hum Vaccin Immunother. 2014;10(6):1669-81. doi: 10.4161/hv.28443. Epub 2014 Mar 17. Hum Vaccin Immunother. 2014. PMID: 24637775 Free PMC article.
-
Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant.Infect Immun. 2008 May;76(5):1952-9. doi: 10.1128/IAI.01722-07. Epub 2008 Feb 19. Infect Immun. 2008. PMID: 18285494 Free PMC article.
-
Radiolabeled antibodies to Bacillus anthracis toxins are bactericidal and partially therapeutic in experimental murine anthrax.Antimicrob Agents Chemother. 2009 Nov;53(11):4860-8. doi: 10.1128/AAC.01269-08. Epub 2009 Aug 24. Antimicrob Agents Chemother. 2009. PMID: 19704133 Free PMC article.
-
Immunization of Mice with Anthrax Protective Antigen Limits Cardiotoxicity but Not Hepatotoxicity Following Lethal Toxin Challenge.Toxins (Basel). 2015 Jun 25;7(7):2371-84. doi: 10.3390/toxins7072371. Toxins (Basel). 2015. PMID: 26120785 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
- R01 AI033142/AI/NIAID NIH HHS/United States
- AI22021/AI/NIAID NIH HHS/United States
- AI33142-11/AI/NIAID NIH HHS/United States
- R01 AI033774/AI/NIAID NIH HHS/United States
- R01 HL059842/HL/NHLBI NIH HHS/United States
- HL59842-07/HL/NHLBI NIH HHS/United States
- AI52733-02/AI/NIAID NIH HHS/United States
- R01 AI052733/AI/NIAID NIH HHS/United States
- R01 AI022021/AI/NIAID NIH HHS/United States
- R56 AI060507/AI/NIAID NIH HHS/United States
- R37 AI033142/AI/NIAID NIH HHS/United States
- AI060507/AI/NIAID NIH HHS/United States
- R01 AI060507/AI/NIAID NIH HHS/United States
- GM07142-01/GM/NIGMS NIH HHS/United States
- AI33774-11/AI/NIAID NIH HHS/United States
- R37 AI022021/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases